Search Results

6.Adverse Effect of Newer Antidepressant ; Nausea and Vomiting, Weight Gain, Sexual Dysfunction: Mechanisms, Epidemiology, and Pharmacological Management.

Korean Journal of Psychosomatic Medicine 2013;21(2):81-92

Newer antidepressants are commonly used in clinical practice to treat psychiatric disorder and psychosomatic disorder including chronic pain syndrome, fibromyalgia, headache. However there are many unexpected adverse effects of these drugs such as nausea and vomiting, weight gain, sexual dysfunction. These are 3 most well-recognized common adverse effects of newer antidepressant and are most common causes of treatment failure. I reviewed mechanisms, epidemiology, and pharmacological management of these adverse effects of newer antidepressants. In this paper, newer antidepressants include selective serotonin reuptake inhibitor(fluoxetine, fluvoxamine, citalopram, escitalopram, sertraline, paroxetine), serotonin norepinephrine reuptake inhibitor(venlafaxine, duloxetine), norepinephrine and dopamine reuptake inhibitor(bupropion), noradrenergic and specific serotonergic antidepressant(mirtazapine), and reversible inhibitor of MAO-A(moclobemide). I suggest that psychiatrists and clinicians in the psychosomatic field should know mechanisms, epidemiology, and management of these common and well-recognized adverse effects of newer antidepressants. Therefore it will be helpful to recognize easily and treat well for patients with psychiatric disorder and psychosomatic disorder using newer antidepressants.
Antidepressive Agents ; Chronic Pain ; Citalopram ; Dopamine ; Epidemiology* ; Fibromyalgia ; Fluvoxamine ; Headache ; Humans ; Nausea* ; Norepinephrine ; Psychiatry ; Psychophysiologic Disorders ; Serotonin ; Sertraline ; Treatment Failure ; Vomiting* ; Weight Gain*

7.Viral inactivation of disinfectant Tego-51(R).

Kyu Man LEE

Korean Journal of Nosocomial Infection Control 1998;3(2):97-100

BACKGROUND: Tego-51(R), one of the amphoteric surfactants, has been considered as an effective disinfectant having both bactericidal and fungicidal effect. The author evaluated inactivation effect of Tego-51(R) on viruses causing disease in humans. METHODS: Influenza virus B, respiratory syncytial virus (RSV), herpes simplex virus 1 (HSV-1), adenovirus and echovirus 30 were exposed to diluted Tego-51(R) solution (1% and 0.1%) for 5, 10 and 30 minutes respectively and were inoculated onto the following cells: Influenza virus B, MDCK; RSV, HEp-2; HSV-1, HEp-2; adenovirus, Vero; and echovirus 30, RD. After incubation for 5 to 6 days, viral infection was identified with indirect immunofluorescent methods. RESULTS: Influenza virus B, RSV and HSV-1 which are enveloped viruses were inactivated after exposure of the viruses to Tego-51(R) for 5 minutes. Non-enveloped adenovirus and echovirus 30 were not inactivated after exposure for 30 minutes. CONCLUSIONS: Tego-51(R) appears to be effective in inactivation of enveloped viruses at concentrations used for disinfection of pathogenic bacteria and fungi.
Adenoviridae ; Bacteria ; Disinfection ; Enterovirus B, Human ; Fungi ; Herpesvirus 1, Human ; Humans ; Orthomyxoviridae ; Respiratory Syncytial Viruses ; Surface-Active Agents ; Virus Inactivation*